Progyny Q1 2024 Adj EPS $0.39 Beats $0.13 Estimate, Sales $278.078M Miss $289.457M Estimate
Portfolio Pulse from Benzinga Newsdesk
Progyny (PGNY) reported Q1 2024 adjusted EPS of $0.39, surpassing the $0.13 estimate, but its sales of $278.078M fell short of the $289.457M forecast. This represents a 7.62% increase in sales compared to the same period last year.
May 09, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Progyny reported a significant beat on EPS estimates but missed on sales forecasts for Q1 2024, with a year-over-year sales increase of 7.62%.
The significant beat on EPS estimates is likely to be viewed positively by investors, indicating strong profitability. However, the miss on sales forecasts could raise concerns about growth prospects, potentially balancing out the positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100